117 related articles for article (PubMed ID: 10678495)
21. The vesamicol receptor ligand (+)-meta-[125I]iodobenzyltrozamicol [(+)-[125I]-MIBT] reveals blunting of the striatal cholinergic response to dopamine D2 receptor blockade in the 6-hydroxydopamine (6-OHDA)-lesioned rat: possible implications for Parkinson's disease.
Efange SM; Langason RB; Khare AB; Low WC
Life Sci; 1996; 58(16):1367-74. PubMed ID: 8614294
[TBL] [Abstract][Full Text] [Related]
22. Chronic effects of single intrastriatal injections of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium studied by microdialysis in freely moving rats.
Espino A; Cutillas B; Tortosa A; Ferrer I; Bartrons R; Ambrosio S
Brain Res; 1995 Oct; 695(2):151-7. PubMed ID: 8556325
[TBL] [Abstract][Full Text] [Related]
23. Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine.
Dethy S; Laute MA; Damhaut P; Goldman S
J Neural Transm (Vienna); 1999; 106(2):145-58. PubMed ID: 10226935
[TBL] [Abstract][Full Text] [Related]
24. Progressive and extensive dopaminergic degeneration induced by convection-enhanced delivery of 6-hydroxydopamine into the rat striatum: a novel rodent model of Parkinson disease.
Oiwa Y; Sanchez-Pernaute R; Harvey-White J; Bankiewicz KS
J Neurosurg; 2003 Jan; 98(1):136-44. PubMed ID: 12546362
[TBL] [Abstract][Full Text] [Related]
25. Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat.
Amalric M; Moukhles H; Nieoullon A; Daszuta A
Eur J Neurosci; 1995 May; 7(5):972-80. PubMed ID: 7613632
[TBL] [Abstract][Full Text] [Related]
26. Intracerebroventricular administration of substance P increases dopamine content in the brain of 6-hydroxydopamine-lesioned rats.
Krasnova IN; Bychkov ER; Lioudyno VI; Zubareva OE; Dambinova SA
Neuroscience; 2000; 95(1):113-7. PubMed ID: 10619467
[TBL] [Abstract][Full Text] [Related]
27. Differential regulation of dopamine release by N-methyl-D-aspartate receptors in rat striatum after partial and extreme lesions of the nigro-striatal pathway.
Andrés ME; Gysling K; Bustos G
Brain Res; 1998 Jun; 797(2):255-66. PubMed ID: 9666143
[TBL] [Abstract][Full Text] [Related]
28. Effects of iptakalim on extracellular glutamate and dopamine levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study.
Yang J; Hu LF; Liu X; Zhou F; Ding JH; Hu G
Life Sci; 2006 Mar; 78(17):1940-4. PubMed ID: 16216278
[TBL] [Abstract][Full Text] [Related]
29. Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats.
Lindner MD; Cain CK; Plone MA; Frydel BR; Blaney TJ; Emerich DF; Hoane MR
Behav Brain Res; 1999 Jul; 102(1-2):1-16. PubMed ID: 10403011
[TBL] [Abstract][Full Text] [Related]
30. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
Yuan H; Sarre S; Ebinger G; Michotte Y
J Neurosci Methods; 2005 May; 144(1):35-45. PubMed ID: 15848237
[TBL] [Abstract][Full Text] [Related]
31. Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Agrawal AK
Neurosci Lett; 2006 May; 398(1-2):44-9. PubMed ID: 16423459
[TBL] [Abstract][Full Text] [Related]
32. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
33. Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF.
Cohen AD; Tillerson JL; Smith AD; Schallert T; Zigmond MJ
J Neurochem; 2003 Apr; 85(2):299-305. PubMed ID: 12675906
[TBL] [Abstract][Full Text] [Related]
34. Effect of lazaroid U-74389G on iron-induced reduction of striatal dopamine metabolism.
Wesemann W; Solbach M; Nafe R; Grote C; Sontag KH; Riederer P; Jellinger K; Mennel HD; Clement HW
J Neural Transm Suppl; 1995; 46():175-82. PubMed ID: 8821053
[TBL] [Abstract][Full Text] [Related]
35. Left/right nigrostriatal asymmetry in susceptibility to neurotoxic dopamine depletion with 6-hydroxydopamine in rats.
Sullivan RM; Szechtman H
Neurosci Lett; 1994 Mar; 170(1):83-6. PubMed ID: 8041518
[TBL] [Abstract][Full Text] [Related]
36. Time-dependent changes in GLT-1 functioning in striatum of hemi-Parkinson rats.
Massie A; Goursaud S; Schallier A; Vermoesen K; Meshul CK; Hermans E; Michotte Y
Neurochem Int; 2010 Nov; 57(5):572-8. PubMed ID: 20643175
[TBL] [Abstract][Full Text] [Related]
37. Specific oxidative stress profile associated with partial striatal dopaminergic depletion by 6-hydroxydopamine as assessed by a novel multifunctional marker molecule.
Aluf Y; Vaya J; Khatib S; Loboda Y; Kizhner S; Finberg JP
Free Radic Res; 2010 Jun; 44(6):635-44. PubMed ID: 20370558
[TBL] [Abstract][Full Text] [Related]
38. The astrocytic response to the dopaminergic denervation of the striatum.
Morales I; Sanchez A; Rodriguez-Sabate C; Rodriguez M
J Neurochem; 2016 Oct; 139(1):81-95. PubMed ID: 27230040
[TBL] [Abstract][Full Text] [Related]
39. Dopaminergic modulation of serotonin metabolism in rat striatum: a study with dopamine uptake inhibitor GBR-12909.
Sivam SP
Life Sci; 1995; 56(26):PL467-72. PubMed ID: 7540709
[TBL] [Abstract][Full Text] [Related]
40. L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors.
Wachtel SR; Abercrombie ED
J Neurochem; 1994 Jul; 63(1):108-17. PubMed ID: 8207420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
